As of close of business last night, AdaptHealth Corp’s stock clocked out at $11.36, up 0.71% from its previous closing price of $11.28. In other words, the price has increased by $+0.08 from its previous closing price. On the day, 867161 shares were traded.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ratios:
To gain a deeper understanding of AHCO’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 19.58 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 10.54. For the most recent quarter (mrq), Quick Ratio is recorded 1.00 and its Current Ratio is at 1.21. In the meantime, Its Debt-to-Equity ratio is 1.57 whereas as Long-Term Debt/Eq ratio is at 1.51.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Jefferies on January 08, 2024, Downgraded its rating to Hold and sets its target price to $8 from $14.50 previously.
On November 08, 2023, BofA Securities Downgraded its rating to Underperform which previously was Neutral and also lowered its target price recommendation from $9.50 to $6.50.
Stifel Downgraded its Buy to Hold on May 10, 2023, whereas the target price for the stock was revised from $18 to $11.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 12 ’24 when Flynn James E sold 114,906 shares for $10.70 per share. The transaction valued at 1,229,494 led to the insider holds 11,528,863 shares of the business.
Flynn James E sold 182,607 shares of AHCO for $2,012,557 on Mar 11 ’24. The 10% Owner now owns 11,643,769 shares after completing the transaction at $11.02 per share. On Mar 08 ’24, another insider, Flynn James E, who serves as the 10% Owner of the company, sold 52,487 shares for $10.93 each. As a result, the insider received 573,652 and left with 11,826,376 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AHCO now has a Market Capitalization of 1.51B and an Enterprise Value of 3.73B. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.47 while its Price-to-Book (P/B) ratio in mrq is 1.03. Its current Enterprise Value per Revenue stands at 1.16 whereas that against EBITDA is -17.69.
Stock Price History:
Over the past 52 weeks, AHCO has reached a high of $15.37, while it has fallen to a 52-week low of $6.37. The 50-Day Moving Average of the stock is 8.73, while the 200-Day Moving Average is calculated to be 9.53.
Shares Statistics:
It appears that AHCO traded 1.15M shares on average per day over the past three months and 1.01M shares per day over the past ten days. A total of 132.63M shares are outstanding, with a floating share count of 70.47M. Insiders hold about 46.98% of the company’s shares, while institutions hold 58.07% stake in the company. Shares short for AHCO as of Feb 29, 2024 were 9.03M with a Short Ratio of 7.18, compared to 10.33M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 6.80% and a Short% of Float of 8.70%.
Earnings Estimates
As of right now, 7 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of $0.05 for the current quarter, with a high estimate of $0.09 and a low estimate of -$0.03, while EPS last year was $0.11. The consensus estimate for the next quarter is $0.2, with high estimates of $0.24 and low estimates of $0.12.
Analysts are recommending an EPS of between $0.93 and $0.51 for the fiscal current year, implying an average EPS of $0.8. EPS for the following year is $1.03, with 7 analysts recommending between $1.31 and $0.67.
Revenue Estimates
In the current quarter, 10 analysts expect revenue to total $769.87M. It ranges from a high estimate of $784.9M to a low estimate of $767M. As of the current estimate, AdaptHealth Corp’s year-ago sales were $744.63M, an estimated increase of 3.40% from the year-ago figure. For the next quarter, 10 analysts are estimating revenue of $821.07M, an increase of 3.50% over than the figure of $3.40% in the same quarter last year. There is a high estimate of $829.62M for the next quarter, whereas the lowest estimate is $813.1M.
A total of 10 analysts have provided revenue estimates for AHCO’s current fiscal year. The highest revenue estimate was $3.35B, while the lowest revenue estimate was $3.3B, resulting in an average revenue estimate of $3.32B. In the same quarter a year ago, actual revenue was $3.2B, up 3.60% from the average estimate. Based on 10 analysts’ estimates, the company’s revenue will be $3.52B in the next fiscal year. The high estimate is $3.66B and the low estimate is $3.45B. The average revenue growth estimate for next year is up 6.10% from the average revenue estimate for this year.
